Neuronetics マネジメント
マネジメント 基準チェック /14
現在、CEO に関する十分な情報がありません。
主要情報
Dan Reuvers
最高経営責任者
n/a
報酬総額
| CEO給与比率 | n/a |
| CEO在任期間 | less than a year |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 1.3yrs |
| 取締役会の平均在任期間 | 4.8yrs |
経営陣の近況
Recent updates
ナラティブの更新 • May 01
STIM: Recalibrated Assumptions And Policy Tailwinds Will Drive Future Repricing
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, profit margins, and future P/E expectations. This results in a slightly lower fair value outlook while keeping the core narrative largely intact.ナラティブの更新 • Apr 16
STIM: Reset Expectations And Higher Discount Rate Will Support Future Repricing
Analysts have lowered their price target on Neuronetics by $4, reflecting updated views on the discount rate, profit margin assumptions, and future P/E levels. Analyst Commentary Bullish Takeaways Bullish analysts view the revised price target as closer to their current assumptions on discount rates and future P/E levels, which they see as a more grounded reflection of Neuronetics' risk profile.
新しいナラティブ • Apr 04
Clinic Margin Pressures And Cash Burn Will Shape This Mental Health Platform’s Eventual Upside
Catalysts About Neuronetics Neuronetics develops and operates NeuroStar TMS systems and Greenbrook mental health clinics that provide device based and drug based treatments for depression and other conditions. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Apr 02
STIM: Updated Discount Rate Assumptions Will Support Bullish Repricing Over Time
Analysts have trimmed their price target on Neuronetics by $4 to reflect updated assumptions on discount rates, margins, and future P/E. This has led to a slightly more cautious outlook on the shares.
新しいナラティブ • Mar 18
Clinic Network And New Therapies Will Transform Mental Health Treatment Over The Next Decade
Catalysts About Neuronetics Neuronetics develops and commercializes NeuroStar TMS systems and operates Greenbrook clinics that provide device based and drug treatments for mental health conditions, including treatment resistant depression. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Mar 18
STIM: Leadership Transition And 2026 Revenue Outlook Will Support Bullish Repricing
Analysts have cut their price target on Neuronetics to $4.33 from $6.50, citing updated assumptions for lower revenue growth at 12.65%, a higher discount rate of 10.04%, a slightly higher profit margin of 13.36%, and a reduced future P/E of 16.22x. What's in the News Neuronetics plans a leadership transition with Dan Reuvers appointed as the next Chief Executive Officer, effective March 23, 2026, while current CEO Keith Sullivan is scheduled to step down on March 23, 2026 and retire on March 31, 2026 after roughly five and a half years leading the company (Key Developments).分析記事 • Jan 07
There's No Escaping Neuronetics, Inc.'s (NASDAQ:STIM) Muted Revenues Despite A 25% Share Price Rise
Neuronetics, Inc. ( NASDAQ:STIM ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...分析記事 • Dec 13
Would Neuronetics (NASDAQ:STIM) Be Better Off With Less Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Nov 14
Slammed 29% Neuronetics, Inc. (NASDAQ:STIM) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Neuronetics, Inc. ( NASDAQ:STIM ) shares are down a considerable 29% in the last...分析記事 • Nov 06
The Neuronetics, Inc. (NASDAQ:STIM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Neuronetics, Inc. ( NASDAQ:STIM ) last week reported its latest third-quarter results, which makes it a good time for...分析記事 • Aug 26
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 29% Lower
Neuronetics, Inc. ( NASDAQ:STIM ) shares have had a horrible month, losing 29% after a relatively good period...分析記事 • Aug 07
Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results
NasdaqGM:STIM 1 Year Share Price vs Fair Value Explore Neuronetics's Fair Values from the Community and select yours...分析記事 • May 15
Why We Think Neuronetics, Inc.'s (NASDAQ:STIM) CEO Compensation Is Not Excessive At All
Key Insights Neuronetics' Annual General Meeting to take place on 22nd of May Total pay for CEO Keith Sullivan includes...分析記事 • May 09
Neuronetics, Inc. (NASDAQ:STIM) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a good week for Neuronetics, Inc. ( NASDAQ:STIM ) shareholders, because the company has just released its...分析記事 • May 04
Neuronetics, Inc.'s (NASDAQ:STIM) 30% Jump Shows Its Popularity With Investors
Neuronetics, Inc. ( NASDAQ:STIM ) shares have continued their recent momentum with a 30% gain in the last month alone...
新しいナラティブ • Apr 09
TMS Acquisition And BMP Expansion Will Transform Treatment Delivery
The acquisition of Greenbrook and expansion of the BMP program are expected to significantly boost revenue through increased patient access and operational efficiency.Seeking Alpha • Mar 30
Neuronetics: Explosive Growth Poised To Soar On FDA Breakthroughs
Summary Neuronetics has shown significant growth, with a 430% rally since November and strong Q4 2024 results, driven by its NeuroStar TMS therapy system. The company's valuation remains attractive despite recent gains, with a forward P/S ratio of 1.71x, well below sector norms, indicating potential undervaluation. Strategic acquisitions, including Greenbrook, and FDA approvals are expected to drive revenue growth and cash flow positivity by Q3 2025. Despite risks like high volatility and competition, Neuronetics' strong market position and growth potential make it a promising investment. Read the full article on Seeking Alpha分析記事 • Mar 06
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 69% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 69% in...分析記事 • Feb 10
Industry Analysts Just Made A Dazzling Upgrade To Their Neuronetics, Inc. (NASDAQ:STIM) Revenue Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) may be thrilled to learn that the analysts have just delivered a...分析記事 • Jan 11
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 43% in...分析記事 • Jan 02
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Nov 18
Neuronetics, Inc. (NASDAQ:STIM) Analysts Just Slashed Next Year's Revenue Estimates By 12%
Market forces rained on the parade of Neuronetics, Inc. ( NASDAQ:STIM ) shareholders today, when the analysts...分析記事 • Nov 05
A Piece Of The Puzzle Missing From Neuronetics, Inc.'s (NASDAQ:STIM) 28% Share Price Climb
Those holding Neuronetics, Inc. ( NASDAQ:STIM ) shares would be relieved that the share price has rebounded 28% in the...分析記事 • Aug 13
Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
The Neuronetics, Inc. ( NASDAQ:STIM ) share price has fared very poorly over the last month, falling by a substantial...分析記事 • May 24
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
Key Insights Neuronetics will host its Annual General Meeting on 30th of May Total pay for CEO Keith Sullivan includes...分析記事 • May 09
The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in Neuronetics, Inc. ( NASDAQ:STIM ) had a terrible week, as shares crashed 28% to US$2.55 in the week...Seeking Alpha • May 09
Neuronetics: Reality Set In
Summary Neuronetics' share price dropped after reporting soft Q1 2024 results, with weak system sales undermining strong treatment demand. Neuronetics' losses remain relatively large, and the company's balance sheet provides it with limited flexibility. The stock may have further to fall if Neuronetics is not able to demonstrate a clear path to profitability in the coming quarters. Read the full article on Seeking Alpha分析記事 • May 08
Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
Neuronetics, Inc. ( NASDAQ:STIM ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • May 01
Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 17
Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Despite an already strong run, Neuronetics, Inc. ( NASDAQ:STIM ) shares have been powering on, with a gain of 26% in...Seeking Alpha • Jan 30
Neuronetics: Modest Improvements Are Not Enough
Summary Neuronetics' stock has rebounded significantly over the past 3 months, although this has been driven more by investor sentiment than company fundamentals. TMS remains underutilized given its efficacy, which should lead to greater adoption in coming years, even if growth is at a relatively modest pace. STIM is still a long way from profitability. Something the company must rectify in the coming quarters. Modest growth and a gradual improvement in profitability will probably not be sufficient to lift the share price higher. Read the full article on Seeking Alpha分析記事 • Dec 19
Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
The Neuronetics, Inc. ( NASDAQ:STIM ) share price has done very well over the last month, posting an excellent gain of...CEO
Dan Reuvers (62 yo)
less than a year
在職期間
Mr. Daniel L. Reuvers, also known as Dan, is CEO, President & Director of Neuronetics, Inc. from March 23, 2026. Mr. Reuvers had been President of Tactile Systems Technology, Inc. since June 8, 2020 until...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | less than a year | データなし | データなし | |
| EVP, Chief Legal Officer & Corporate Secretary | 6.3yrs | US$2.11m | 0.55% $ 459.5k | |
| Senior VP & Chief of Operations | 1.3yrs | データなし | データなし | |
| SVP & Chief Technology Officer | 1.3yrs | データなし | データなし | |
| Senior VP & Chief Marketing Officer | 3yrs | データなし | データなし |
1.3yrs
平均在職期間
62yo
平均年齢
経験豊富な経営陣: STIMの経営陣は 経験豊富 とはみなされません ( 1.3年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | less than a year | データなし | データなし | |
| Independent Director | 8.8yrs | US$204.11k | 0.40% $ 336.5k | |
| Independent Director | 6.6yrs | US$201.61k | 0.19% $ 156.4k | |
| Independent Chairman of the Board | 5.1yrs | US$268.23k | 0.79% $ 663.0k | |
| Independent Director | 1.4yrs | US$119.70k | 0.018% $ 15.0k | |
| Independent Director | 1.4yrs | US$183.97k | 2.88% $ 2.4m | |
| Independent Director | 4.8yrs | US$197.56k | 0.16% $ 133.1k |
4.8yrs
平均在職期間
62yo
平均年齢
経験豊富なボード: STIMの 取締役会 は 経験豊富 であると考えられます ( 4.8年の平均在任期間)。
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/24 19:15 |
| 終値 | 2026/05/22 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Neuronetics, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3
| アナリスト | 機関 |
|---|---|
| William Plovanic | Canaccord Genuity |
| Daniel Stauder | Citizens JMP Securities, LLC |
| Adam Maeder | Piper Sandler Companies |